MHRA Board Conflicted to Hell and Back—Gates, Big Pharma, WHO, Microsoft, NHS—All Serving their Masters, not Patient Safety
Check out MHRA Board Declarations of Interest – May 2023
This will shock you to the core, no matter where you are
What follows below shocked me to the core, and may well do the same for you. I’ve long been banging on about the UK being the epicentre of Gates’ global healthcare and life science empire. Part of that is his ownership of the people that are on the MHRA Board….as non-executive directors. Subscribers can read more on that below:
The MHRA Board Declarations of Interest – May 2023 shines a spotlight on the degree of conflicted and vested interests there are on the Board. You may not be surprised to read the ‘disclaimer’.
The Board and its Non-Executive Directors have no involvement in any regulatory decisions affecting medicines, medical devices or any other products or services delivered by the Agency. These decisions are the responsibility of the Chief Executive Officer, supported by the Executive Committee.
That’s the Executive Committee thrown under the bus then…
…but hang on, are they saying that the non-executive directors have no influence on the decisions taken by the Executive Committee? Judge that for yourself…
…especially when you read the below extracted from the MHRA Board Declarations of Interest – May 2023:
Dr Junaid Bajwa, Non-Executive, Director
Microsoft Employed (Chief Medical Scientist at Microsoft Research), Shareholder
Merck Sharp and Dohme Ex-employee shareholder
Ondine biomedical, Non-Executive Director
Novartis Industry Council Advisory to UK Pharma Exec UCLH, Non-Executive Director
Whittington NHS Trust Associate Non-Executive Director
NHS GP, Physician (Sessional)
Nuffield Health Governor (NED)
Nahdi Medical Corporation Non-Executive Director
DIA Global Board Member
Amanda Calvert, Non-Executive, Director
Astrazeneca Ex-employee shareholder, Immediate family member
Quince Consultancy Ltd Provides consultancy services including companies in the healthcare sector.
Athenex Pharma Quince Consultancy, providing strategic consultancy on oral oncology chemotherapy platform. ILAP applicant and Marketing Authorisation applicant.
University of Manchester digital Experimental Cancer Medicine Team, Quince Consultancy providing strategy and data protection consultancy
Cambridge Judge Business School, Member of Advisory Board
Fennix Pharmaceuticals Founder of start-up company planning to develop oral chemotherapy product into Phase 2 trial. Not yet trading.
High Value Manufacturing Catapult, Non-Executive Director
Professor Graham Cooke, Non-Executive Director & Deputy Chair
Imperial College NHS Trust and Chelsea & Westminster NHS Foundation Trust,
Honorary NHS Consultant NIHR NIHR Research Professor
NIHR Influenza platform trial in the UK
NIHR Chair DSMB (PROTECT-V trial)
Pfizer Pneumonia study with Imperial College Healthcare Partners
30 Technology Ltd Consultant/Advisor
DNAnudge Ltd Consultant/Advisor
Seventh Sense Biosystems Consultant/Advisor
Debevoise and Plimpton LLP Consultant/Advisor in relation to COVID protocols
Sanofi CoV Chair of End Point Review Committee for vaccine trial
WHO Chair of Committee for Selection and Use of Essential Medicines
Dr Paul Goldsmith, Non-Executive Director,
Closed Loop Medicine Ltd Shareholder, director & employee; MA submission
Summit Inc Shareholder
Ieso Digital Health Shareholder
MDU Ltd Director
MDU Investments Ltd Director
NHS Consultant Neurologist
NHS Clinical Senate Member
Radix Big Tent Foundation Trustee
Sleepstation Co-founder of original programme, 2012-2014
Raj Long, Non-Executive Director
Gates Foundation Employee – Deputy Director
Bristol-Myers Squibb Ex-Employee Shareholder
RESOLVE (Sustainable solutions to critical social, health, and environmental challenges) Scientific Advisory
Novartis Ex-Employee Shareholder
EC IMI NEURONET EC Innovative Medicines Initiative (IMI) Non-Product, Scientist Advisory Board
Gates Venture – EC Innovative Medicines Initiative (IMI) Non-Product – IMI European platform for Neurodegenerative Disorders Advisory
HUYA Bio Access Advisory
PAVIA – PV Africa Board (EC Funded) Advisory Board
WHO – Sustainable COVAX Manufacturing Strategy for Regional Health Security Advisory Expert
UK Health Security Agency Associate Non-Executive Board Member
MHRA Leadership Team is not qualified
If that’s not enough, the CEO and Executive Committee carries the can for all decisions, and magically, they have no conflicts listed in the MHRA Board Declarations of Interest – May 2023. Sadly, however, they have not got the qualifications to do the piece they are employed to do, declared above:
Decisions are the responsibility of the Chief Executive Officer, supported by the Executive Committee.
Let’s take a deeper dive into their qualifications:
Dame June Raine DBE (Chief Executive):
“She was elected in 2012 as the first chair of the European Pharmacovigilance Risk Assessment Committee and is also co-Chair of the WHO Advisory Committee on Safety of Medicinal Products. Her special interests are in monitoring the outcomes of regulatory action, risk communication and patient involvement in the regulatory process.” Previous appointment:
“Director of Vigilance and Risk Management of Medicines, 1999 to 2019”
That means she has no experience of the approval process for medicinal products, nothing, zilch, zippo, nowt.
Hopefully, Raine’s second-in-command has a better handle on things:
Laura Squire (Chief Healthcare Quality and Access Officer)
“She has spent most of her career as a Civil Servant… She joined the Medicines and Healthcare products Regulatory Agency from the Department of Health and Social Care, where she worked extensively on the COVID-19 vaccine deployment programme.”
Whoops, if it were possible, even less experience than Dame Raine.
Marc Bailey (Chief Science and Innovation Officer)
“Marc is a molecular biologist with a PhD in Pathology. Marc has had a varied career starting with academic research on infectious diseases before establishing a team developing physical standards for biotechnology at the National Physical Laboratory and then leading research into Digital Health for a multinational corporation.”
Even more deep science, without a scooby doo of the regulatory processes required to bring safe, effective products to market.
Claire Harrison (Chief Digital and Technology Officer)
No biography? Does she have one?
Alison Cave (Chief Safety Officer)
“Alison is a pharmacologist with a PhD in biochemistry. Her long career includes significant academic and regulatory experience, the latter initially at the Medicines Control Agency and then in senior roles within the Vigilance and Risk Management of Medicine Group at the MHRA and the European Medicines Agency (EMA). In addition she was Head of Cellular, Developmental and Physiological Sciences at the Wellcome Trust and most recently an Industrial Strategy Challenge Fund Director at UK Research and Innovation.”
Another pharmacologist and pharmacovigilance specialist, worked at the now infamous Wellcome Trust under Jeremy Farrar’s leadership.
Glenn Wells (Chief Partnerships Officer)
“Prior to the MRC Glenn also built partnerships while working for the Oxford Academic Health Science Centre and the Wellcome Trust. In addition, Glenn developed an extensive knowledge of legal frameworks for healthcare systems through his work as a senior civil servant in DHSC delivering the Health and Social Care Act 2012.”
Another Wellcome Trust plant, courtesy Jeremy Farrar.
What should we make of this?
Well, firstly, MHRA was the world’s first regulatory authority to approve the poison jabs. People in other countries, such as the US, would be well advised to clock the link between the UK and the global launch of the gene therapies.
I’d just love to interview the MHRA ‘top team’ and expose their complete lack of knowledge, experience and any semblance of moral compass.
It’s on my Christmas list….
More to come soon.
Dr Junaid Bajwa has registered multiple identities in Companies House (see https://find-and-update.company-information.service.gov.uk/search?q=Junaid+Bajwa). He fails to declare that he's recently been a director of ECONSULT HEALTH LIMITED and VISIONABLE LTD (see https://find-and-update.company-information.service.gov.uk/officers/mQzqtuWuPlnBcTPx2rQ1wWs5U-M/appointments). He has another identity which was appointed to ESSENTIAL LIFE ADVICE LIMITED (https://find-and-update.company-information.service.gov.uk/officers/8Fz4P83vy1lQW6FzAcNBgrZuv_w/appointments). The interests that he declares are in his third identity, eg Nuffield Health (https://find-and-update.company-information.service.gov.uk/officers/sOKneSdt5WYrbJv1WdP5qtTSptY/appointments), and he fails to declare some of these; UNIVERSITY COLLEGE LONDON HOSPITALS CHARITY (09980449) Active, PENINSULA HEALTHCARE (UK) LIMITED (09082491) Active, PROSPECT HEALTH APB LIMITED (06888003) Dissolved, ESSENTIAL GUIDES UK LIMITED (06608543) Active, MEDICA GROUP LIMITED (08497963) Recently resigned, GREENWICH PRIMARY CARE COLLABORATIVE CIC (06900486) In liquidation, and BEHAVIOUR LABS LTD (08899713) Dissolved. He claims to be a director of Ondine Biomedical Limited, when he is not appointed as such in Companies House (https://find-and-update.company-information.service.gov.uk/company/10570442/officers). This entry in the Register of Interests could enable a permission incorrectly and is another red flag for fraud. He has made other entries that are not supported by Companies House. He is not a director of Nahdi Medical Corporation and he is not a director of DIA Global (he is not a director of any of the companies with these names https://find-and-update.company-information.service.gov.uk/search/companies?q=DIA+Global+). These false submissions in his register of interests can also allow a permission when it should be denied (an error which is called a false match error). I conclude that Dr Junaid Bajwa has committed two counts of identity fraud and has committed fraud by failing to disclose information. Because multiple identities compromise all audits and due diligence associated to the him and his interests, Dr Bujwa is not a fit and proper person. He should resign and be investigated by the police for fraud, together with all officers who have registered multiple identities. This is a method of fraud that takes advantage of false non-match errors and false match errors in IT systems. It works by concealing interests from audit and due diligence software. Minimising these errors is Companies House's duty, instead the Minister in charge, Kevin Hollinrake, has multiple identities and has failed to declare interests. See https://alisonwright.substack.com/p/due-diligence-on-kevin-hollinrake
So what you're saying is: All of the people promoting the death jabs and covering up the evidence of the injuries and deaths cause by them, are highly incentivized to CONTINUE maiming and murdering people and CONTINUE covering up the injuries and deaths?